Welcome!

News Feed Item

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/648928/Coronary-Vasospasm-Global-Clinical-Trials-Review-H2-2014.html

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Vasospasm Global Clinical Trials Review, H2, 2014" provides data on the Coronary Vasospasm clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Vasospasm. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Vasospasm. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Coronary Vasospasm 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Coronary Vasospasm 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Coronary Vasospasm Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
Pfizer Inc. 27
Clinical Trial Overview of Pfizer Inc. 27
Clinical Trial Overview of Top Institutes / Government 28
Japanese Coronary Spasm Association 28
Clinical Trial Overview of Japanese Coronary Spasm Association 28
Robert Bosch Medical Center 29
Clinical Trial Overview of Robert Bosch Medical Center 29
Kyorin University 30
Clinical Trial Overview of Kyorin University 30
Kumamoto University 31
Clinical Trial Overview of Kumamoto University 31
National Institute of Health and Medical Research 32
Clinical Trial Overview of National Institute of Health and Medical Research 32
University of Nebraska 33
Clinical Trial Overview of University of Nebraska 33
Korea University 34
Clinical Trial Overview of Korea University 34
University Hospital Basel 35
Clinical Trial Overview of University Hospital Basel 35
Washington University School of Medicine 36
Clinical Trial Overview of Washington University School of Medicine 36
University of California, San Francisco 37
Clinical Trial Overview of University of California, San Francisco 37
Five Key Clinical Profiles 38
Appendix 55
Abbreviations 55
Definitions 55
Research Methodology 56
Secondary Research 56
About GlobalData 57
Contact Us 57
Disclaimer 57
Source 57

List of Tables
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Region, 2014* 6
Coronary Vasospasm Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Vasospasm Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Coronary Vasospasm Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Coronary Vasospasm Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Coronary Vasospasm Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 13
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 16
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Coronary Vasospasm Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Coronary Vasospasm Therapeutics, Global, Suspended Clinical Trials, 2014* 21
Coronary Vasospasm Therapeutics, Global, Withdrawn Clinical Trials, 2014* 21
Coronary Vasospasm Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Coronary Vasospasm Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Coronary Vasospasm Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Coronary Vasospasm Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 25
Coronary Vasospasm Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 26
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 27
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Japanese Coronary Spasm Association, 2014* 28
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Robert Bosch Medical Center, 2014* 29
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyorin University, 2014* 30
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Kumamoto University, 2014* 31
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Health and Medical Research, 2014* 32
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Nebraska, 2014* 33
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Korea University, 2014* 34
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Basel, 2014* 35
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 36
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 37

List of Figures
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Coronary Vasospasm Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Vasospasm Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Coronary Vasospasm Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Coronary Vasospasm Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 13
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 16
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Coronary Vasospasm Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Coronary Vasospasm Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
Coronary Vasospasm Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
GlobalData Methodology 56

Read the full report:
Coronary Vasospasm Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/648928/Coronary-Vasospasm-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, will provide a fun and simple way to introduce Machine Leaning to anyone and everyone. Together we will solve a machine learning problem and find an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intellige...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
Digital transformation is changing the face of business. The IDC predicts that enterprises will commit to a massive new scale of digital transformation, to stake out leadership positions in the "digital transformation economy." Accordingly, attendees at the upcoming Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA, Oct 31-Nov 2, will find fresh new content in a new track called Enterprise Cloud & Digital Transformation.
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
Though cloud is the future of enterprise computing, a smooth transition of legacy applications and systems is critical for seamless business operations. IT professionals are eager to start leveraging the cost, scale and other benefits of cloud, but with massive investments already in place in existing infrastructure and a number of compliance and resource hurdles, it can be challenging to move to a cloud-based infrastructure.
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, will discuss how given the magnitude of today's applicati...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Amazon is pursuing new markets and disrupting industries at an incredible pace. Almost every industry seems to be in its crosshairs. Companies and industries that once thought they were safe are now worried about being “Amazoned.”. The new watch word should be “Be afraid. Be very afraid.” In his session 21st Cloud Expo, Chris Kocher, a co-founder of Grey Heron, will address questions such as: What new areas is Amazon disrupting? How are they doing this? Where are they likely to go? What are th...